Almirall SA (LBTSF)
15.35
0.00 (0.00%)
USD |
OTCM |
Aug 27, 16:00
Almirall Gross Profit Margin (Quarterly) : 25.76% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 25.76% |
| December 31, 2025 | |
| June 30, 2025 | |
| December 31, 2024 | |
| June 30, 2024 | |
| December 31, 2023 | |
| June 30, 2023 | |
| December 31, 2022 | |
| June 30, 2022 | |
| December 31, 2021 | |
| June 30, 2021 | |
| December 31, 2020 | |
| June 30, 2020 |
| Date | Value |
|---|---|
| December 31, 2019 | |
| June 30, 2019 | |
| December 31, 2018 | |
| June 30, 2018 | |
| December 31, 2017 | |
| June 30, 2017 | |
| December 31, 2016 | |
| June 30, 2016 | |
| December 31, 2015 | 66.87% |
| June 30, 2015 | 68.06% |
| December 31, 2014 | 4.12% |
| June 30, 2014 | 71.05% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Laboratorios Farmaceúticos Rovi SA | 63.56% |
| Eli Lilly & Co. | 85.78% |
| AstraZeneca PLC | 76.09% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 4.13% |
| Profit Margin (Quarterly) | 7.78% |
| Operating Margin (Quarterly) | 12.81% |